DrugPipeline.net has announced the addition of “Hemophilia A - Pipeline Review, H1 2018” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWire) -- 06/21/2018 --Hemophilia A - Pipeline Review, H1 2018, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights
Hemophilia A - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 4, 24, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 182 pages "Hemophilia A - Pipeline Review, H1 2018" report covers Introduction, Hemophilia A - Overview, Hemophilia A - Therapeutics Development, Hemophilia A - Therapeutics Assessment, Hemophilia A - Companies Involved in Therapeutics Development, Hemophilia A - Drug Profiles, Hemophilia A - Dormant Projects, Appendix. This report Covered Companies few are - Amarna Therapeutics BV, Apitope International NV, Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Casebia Therapeutics, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, EpiVax Inc, Expression Therapeutics LLC, GC Pharma, ID Pharma Co Ltd.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/hemophilia-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - https://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Obesity - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/obesity-pipeline-review-h1-2018

Systemic Lupus Erythematosus - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/systemic-lupus-erythematosus-pipeline-review-h1-2018

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.